The Full Wiki

More info on Fluticasone propionate

Fluticasone propionate: Wikis

Advertisements
  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Fluticasone propionate
Systematic (IUPAC) name
S-(fluoromethyl)-6α,9-difluoro-11β, 17-dihydroxy-16α-methyl-3-oxoandrosta-1, 4-diene-17β-carbothioate, 17-propionate
Identifiers
CAS number 80474-14-2
ATC code D07AC17 & D07AC04 (topical)
PubChem 5311101
DrugBank APRD00065
Chemical data
Formula C 25H31F3O5S 
Mol. mass 500.57 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 0.51% (Intranasal)
Protein binding 91%
Metabolism Intranasal
Hepatic (CYP3A4-mediated)
Half life 10 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat. C for Intranasal and Inhaled
Legal status POM (UK) Rx Only (US)
Routes Intranasal, Inhaled, Topical Cream or Ointment
 Yes check.svgY(what is this?)  (verify)

Fluticasone propionate is a synthetic corticosteroid derived from fluticasone used to treat asthma and allergic rhinitis.

GlaxoSmithKline currently markets fluticasone propionate as Flovent (USA and Canada) and Flixotide (EU) for asthma, and as Flonase (USA and Canada) Flixonase (EU and Brazil) for allergic rhinitis, as well as a combination of fluticasone and salmeterol as Advair (USA and Canada) or Seretide (EU).

It is also available as a cream (marketed as Cutivate or Flutivate) for the treatment of eczema and psoriasis.

Contents

Flonase patent issues

GlaxoSmithKline's patent on Flonase expired in May 2004. The Food and Drug Administration (FDA) approved the sale of a generic version of Flonase on February 22, 2006. On February 23, 2006, GlaxoSmithKline (GSK) was able to obtain a temporary 10-day restraining order from a federal judge in Baltimore blocking the shipment and sales of the approved generic versions of Flonase. The restraining order lasted until March 6, 2006. The basis of the complaint by GSK was that the FDA failed to follow its own regulations in approving the generics and failed to apply the same quality standards for the generic version as it did for Flonase. GSK made these arguments in petitions filed with the FDA, but the FDA rejected those petitions. The Maryland District Court denied the request by GSK to extend the ban on Flonase generics beyond March 6, 2006, and GSK released a statement that they would not appeal the ruling.[1] The ruling meant that sales of generic versions of Flonase could proceed.

Side Effects

In studies the topical drug has been shown to cause burning, stinging, skin irritation, blisters, dryness, skin infection, infected eczema, viral warts, impetigo, atopic dermatitis, pruritus, exacerbation of pruritus, exacerbation of eczema, erythema, and folliculitis. [2]

Side effects of the nostril spray version include headache, throat infection, nasal irritation, sneezing, cough, nausea, vomiting, nosebleeds, skin rash, itching, facial swelling, and anaphylaxis. It can also cause growth suppression in children.[3]

See also

References

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message